New hope for bile duct cancer: drug combo shows promise in halting tumor growth
NCT ID NCT04005339
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a combination of three drugs (fluorouracil, leucovorin, and nanoliposomal irinotecan) in 48 adults with advanced bile duct or gallbladder cancer that has worsened after standard chemotherapy. The main goal is to see if the treatment can stop the cancer from growing for at least 4 months. Participants must have tried only one prior chemotherapy and be in good overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Washington University School of Medicine- Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.